Showing 771-780 of 8860 results for "".
Treating Moderate to Severe Psoriasis: Weighing the Treatment Options
https://practicaldermatology.com/topics/psoriasis/-treating-moderate-to-severe-psoriasis-weighing-the-treatment-options/18375/In part 2 of her interview with DermTube Journal Club host Joshua Zeichner, MD, Erin Boh, MD reviews new biologics that provide patients with moderate to severe psoriasis improved treatment options. She discusses their efficacy and safety and offers tips for finding the right one for each patient baNRS: New Rosacea Classification; Pediatric Teledermatology; Bleach Baths
https://practicaldermatology.com/series/dermwire-tv/nrs-new-rosacea-classification-pediatric-teledermatology-bleach-baths/18394/There's a new standard classification and pathophysiology of rosacea from the National Rosacea Society. New evidence shows that virtual diagnosis of pediatric dermatologic conditions is feasible. New research suggests that water baths may be just as good as bleach baths for treating eczema. ResearchHow Do You Manage the Aesthetic Patient?
https://practicaldermatology.com/topics/practice-management/how-do-you-manage-the-aesthetic-patient/18775/Managing the aesthetic patient is all about building relationships explains Joel L. Cohen, MD, founder of AboutSkin Dermatology in Englewood, CO. Dr. Cohen speaks with host Adam Friedman, MD, Associate Professor of Dermatology, Director, Residency Program, and Director, Translational Research at TheTips for Thriving in Your First Years of Practice
https://practicaldermatology.com/topics/practice-management/tips-for-thriving-in-your-first-years-of-practice/18826/Salma Pothiawala, MD, recipient of a grant for Residents and Fellows, shares tips to help dermatologists new to practice thrive in their early years.DermwireTV — Nestle acquires Galderma; Dermatologic procedures surge
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-mdash-nestle-acquires-galderma-dermatologic-procedures-surge/19157/In this edition of DermWireTV, from the publishers of Practical Dermatology® magazine: Nestle acquires Galderma, dermatologic procedures surge, and we look ahead to the annual meeting in Denver. #DermWireAlma Lasers Dye-PL Applicator for the HarmonyXL Platform
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/alma-lasers-dye-pl-applicator-for-the-harmonyxl-platform-/19243/Dye-PL is a new pulsed light applicator from Alma Lasers that concentrates the wavelength into a narrow filter of 100 nm, providing Dye Laser results, with the safety and efficiency of light.Navigating Industry: Tips for Successful Relationships and Partnerships
https://practicaldermatology.com/issues/january-february-2025/navigating-industry-tips-for-successful-relationships-and-partnerships/32976/Dermatology is no longer confined to the physician-patient interaction in a busy clinic, private practice office, or academic center.How to Discuss Isotretinoin’s Safety Profile With Acne Patients
https://practicaldermatology.com/conferences/maui-derm-2024/how-to-discuss-isotretinoins-safety-profile-with-acne-patients/20237/Acne Symposium moderator Guy Webster, MD, PhD, clinical professor of dermatology at Thomas Jefferson University, explains how he helps adolescent patients with the most severe cases of acne manage the potential side effects of isotretinoin.DermWireTV: Sotyktu Approval, Cetaphil at 75, Psoriasis/Depression Link
https://practicaldermatology.com/topics/psoriasis/dermwiretv-sotyktu-approval-cetaphil-at-75-psoriasisdepression-link/20138/FDA has approved Bristol Myers Squibb’s Sotyktu (deucravacitinib) for the oral treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. April Armstrong, MD discusses the first TYK-2 inhibitor approved for psoriasis. As Cetaphil (Galderma)DermWireTV: Cosentyx for Kids; Anifrolumab for SLE, Tremfya in PsA at EULAR
https://practicaldermatology.com/topics/psoriasis/dermwiretv-cosentyx-for-kids-anifrolumab-for-sle-tremfya-in-psa-at-eular/19948/FDA has approved Cosentyx (secukinumab) from Novartis for patients as young as six years old. The 2nd Annual San Diego Dermatology Symposium kicks off as a live Virtual Experience next Friday. A post-hoc analysis of pooled data from the TULIP Phase 3 clinical trials shows that anifrolumab improves